{
  "id": "nsclc-pd1-main",
  "display_name": "NSCLC PD-L1≥50% (Main)",
  "cohort": "NSCLC PD-L1 ≥ 50%, First Line, Q1 2023",
  "insight_type": "Treatment Patterns by Regimen",
  "summary": "Pembrolizumab monotherapy utilization is at 75% for eligible patients, slightly below NCCN guidelines recommendation of 85%.",
  "recommendation": "Consider increasing pembrolizumab monotherapy utilization for eligible patients with PD-L1 ≥ 50%.",
  "financial_impact": {
    "annual_opportunity": "$120,000/year",
    "math": "Increasing pembrolizumab monotherapy could save approximately $120,000 annually by avoiding unnecessary combination therapies."
  },
  "financial_impact_description": "Increasing pembrolizumab monotherapy could save approximately $120,000 annually by avoiding unnecessary combination therapies.",
  "peer_financial_impact": 180000,
  "peer_financial_impact_description": "Your organization is slightly below peer performance, representing potential savings of $180,000 annually.",
  "action_steps": [
    {
      "text": "Review patient selection criteria for pembrolizumab monotherapy",
      "icon": "chart-bar"
    },
    {
      "text": "Conduct provider education on NCCN guidelines for PD-L1 ≥ 50% patients",
      "icon": "user-group"
    },
    {
      "text": "Implement pathway alerts for eligible patients",
      "icon": "star"
    }
  ],
  "peer_action_steps": [
    "Benchmark against top-performing organizations",
    "Develop a specific action plan to increase appropriate monotherapy use",
    "Monitor progress monthly"
  ],
  "chart_data": {
    "categories": [
      "Pembrolizumab",
      "Chemo+IO",
      "Chemo only",
      "Atezolizumab",
      "Other"
    ],
    "values": [
      75,
      15,
      5,
      3,
      2
    ],
    "peer_values": [
      82,
      10,
      3,
      3,
      2
    ],
    "target_values": [
      85,
      10,
      0,
      5,
      0
    ]
  },
  "drilldowns": [
    {
      "label": "View by Payer",
      "description": "Compare regimen utilization by payer type",
      "jsonFile": "nsclc-pd1-by-payer.json"
    }
  ],
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      {
        "name": "Pembrolizumab",
        "value": 75,
        "gap": 0,
        "highlight": true
      },
      {
        "name": "Chemo+IO",
        "value": 15,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Chemo only",
        "value": 5,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Atezolizumab",
        "value": 3,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Other",
        "value": 2,
        "gap": 0,
        "highlight": false
      }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "clinical_impact": {
    "description": "Clinical impact analysis based on outcomes data and peer-reviewed literature.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+3.2 months",
        "description": "Potential median progression-free survival improvement"
      },
      {
        "type": "OS",
        "value": "+5.1 months",
        "description": "Potential median overall survival improvement"
      },
      {
        "type": "QoL",
        "value": "+15%",
        "description": "Enhanced quality of life measures"
      }
    ],
    "quantitative": "+5.1 months OS"
  },
  "weighted_score": 78
}